We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+7.51%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.46B
AUM Growth
-$38.8M
Cap. Flow
-$22M
Cap. Flow %
-1.5%
Top 10 Hldgs %
61.18%
Holding
86
New
16
Increased
26
Reduced
28
Closed
12

Top Buys

Rank Stock Value
1
INSM icon
Insmed
INSM
+$44.8M
2
RGEN icon
Repligen
RGEN
+$29.2M
3
INSP icon
Inspire Medical Systems
INSP
+$21.3M
4
NVO
Novo Nordisk
NVO
+$11.2M
5
HCA icon
HCA Healthcare
HCA
+$10.3M

Top Sells

Rank Stock Value
1
NTRA icon
Natera
NTRA
+$61.4M
2
PFE icon
Pfizer
PFE
+$30.6M
3
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
+$26.2M
4
TEVA icon
Teva Pharmaceuticals
TEVA
+$20.1M
5
THC icon
Tenet Healthcare
THC
+$18.5M

Sector Composition

Rank Sector Weight
1 Healthcare 88.85%
2 Miscellaneous 11.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVRO
51
DELISTED
NEVRO CORP.
NVRO
$4.2M 0.29%
499,395
+109,732
+28% +$1.17M
ICLR icon
52
Icon
ICLR
$13.1B
$3.96M 0.27%
12,642
-2,705
-18% -$848K
MRUS
53
DELISTED
Merus
MRUS
$3.93M 0.27%
66,474
-53,008
-44% -$2.57M
MLTX icon
54
MoonLake Immunotherapeutics
MLTX
$1.28B
$3.15M 0.22%
+71,596
New +$3.03M
AMRN
55
Amarin Corp
AMRN
$295M
$2.96M 0.2%
215,426
-95,211
-31% -$1.64M
GH icon
56
Guardant Health
GH
$21.7B
$2.87M 0.2%
99,377
-350,209
-78% -$8.15M
IFRX icon
57
InflaRx
IFRX
$329M
$2.73M 0.19%
1,566,930
+261,790
+20% +$384K
AVTR icon
58
Avantor
AVTR
$9.86B
$2.66M 0.18%
125,394
– –
TRML
59
DELISTED
Tourmaline Bio
TRML
$2.63M 0.18%
+204,781
New +$3.3M
IQV icon
60
IQVIA
IQV
$43.1B
$2.57M 0.18%
12,178
– –
ALEC icon
61
Alector
ALEC
$261M
$2.46M 0.17%
541,739
+5,568
+1% +$28.7K
IMVT icon
62
Immunovant
IMVT
$8.51B
$2.45M 0.17%
92,909
-162,617
-64% -$4.63M
XOMA
63
DELISTED
Xoma
XOMA
$2.18M 0.15%
91,907
-5,158
-5% -$129K
AUTL
64
Autolus Therapeutics
AUTL
$623M
$2.13M 0.15%
+610,902
New +$2.64M
TERN
65
DELISTED
Terns Pharmaceuticals
TERN
$1.95M 0.13%
286,266
+3,232
+1% +$19.6K
MREO
66
Mereo BioPharma
MREO
$40.3M
$1.79M 0.12%
+496,171
New +$1.61M
KURA icon
67
Kura Oncology
KURA
$1.13B
$1.49M 0.1%
+72,317
New +$1.49M
ABSI icon
68
Absci
ABSI
$1.49B
$1M 0.07%
+325,509
New +$1.51M
FULC icon
69
Fulcrum Therapeutics
FULC
$294M
$948K 0.06%
+152,965
New +$1.16M
AFMD
70
DELISTED
Affimed
AFMD
$907K 0.06%
166,460
– –
STOK icon
71
Stoke Therapeutics
STOK
$2.04B
$828K 0.06%
61,277
-228,723
-79% -$3.09M
GTHX
72
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$456K 0.03%
+199,963
New +$764K
ACIU icon
73
AC Immune
ACIU
$263M
$396K 0.03%
99,313
-25,276
-20% -$83.6K
MCRB icon
74
Seres Therapeutics
MCRB
$51.3M
$303K 0.02%
20,910
-48,537
-70% -$810K
JBIO
75
Jade Biosciences
JBIO
$1.33B
– –
-1,547
Closed -$1.6M
1 2
3
4

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q2 2024 Portfolio in Review

As of Q2 2024, Eversept Partners held 86 positions worth $1.46B, down 2.6% from $1.5B the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Eversept Partners's Q2 2024 filing shows 16 new, 26 increased, 28 reduced and 12 closed positions. Its largest new stake was Insmed: 1,155,588 shares worth $77.4M. The largest sale was Natera, an estimated $61.4M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 89% a quarter earlier, followed by Miscellaneous.

  • Eversept Partners's largest Q2 2024 buy was Insmed: 1,155,588 shares worth $77.4M.
  • Eversept Partners added most to Repligen in Q2 2024, an estimated $29.2M increase.
  • Eversept Partners's biggest Q2 2024 reduction was Natera, cutting an estimated $61.4M.
  • Eversept Partners fully exited Pfizer in Q2 2024, selling an estimated $30.6M.
  • Eversept Partners's ten largest holdings make up 61% of its $1.46B portfolio in Q2 2024.
  • Eversept Partners opened 16 new positions and closed 12 in Q2 2024.
  • Eversept Partners's portfolio value fell 2.6% quarter-over-quarter to $1.46B.

Based on Eversept Partners's 13F filing for Q2 2024, filed 14 Aug 2024.